Pfizer and
BioNTech triumphed in the bid to revoke
CureVac's UK COVID vaccine patents. Additionally,
BioNTech's ADR performance surpassed market expectations on several days, even as it faced legal actions seeking 'full royalty payments' for the COVID-19 vaccine. Amid's COVID vaccine sales downward trend, it's shifting its focus towards oncology, with hopes pinned on delivering a successful mRNA-based lung cancer vaccine that has launched global trials. The company also plans to strengthen Africa's mRNA vaccine ecosystem through a strategic partnership with
CEPI. Novelties like 'AI lab assistants' in collaboration with
DeepMind aims to revolutionize scientific research. Yet, the desired impact of a combined flu-COVID vaccine candidate failed to achieve the main goal of Phase 3 trial, leading to setbacks. BioNTech now projects a return to revenue growth in 2025, based on its expansion strategy and the strength of its pipeline. However, as per FDA's notice, there are concerns around 'significant risk of illness' in ongoing trials of BioNTech's cancer drug. While the EU awaits approval of BioNTech’s Omicron vaccine, notable competitors like
Moderna manage to secure wins in COVID-19 patent disputes.
BIONTECH News Analytics from Mon, 20 Nov 2023 19:17:53 GMT to Sun, 13 Oct 2024 01:18:29 GMT -
Rating 4
- Innovation 8
- Information 7
- Rumor 3
